Ameriprise Financial Inc. Purchases 753,865 Shares of Cigna Group $CI

Ameriprise Financial Inc. boosted its position in Cigna Group (NYSE:CI) by 54.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,136,311 shares of the health services provider’s stock after acquiring an additional 753,865 shares during the period. Ameriprise Financial Inc. owned 0.80% of Cigna Group worth $615,781,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dodge & Cox grew its position in shares of Cigna Group by 4.0% during the 3rd quarter. Dodge & Cox now owns 9,305,225 shares of the health services provider’s stock worth $2,682,231,000 after buying an additional 354,615 shares during the period. Sanders Capital LLC lifted its holdings in Cigna Group by 0.5% in the third quarter. Sanders Capital LLC now owns 7,828,168 shares of the health services provider’s stock valued at $2,256,469,000 after buying an additional 35,150 shares during the period. Norges Bank bought a new position in Cigna Group in the second quarter valued at approximately $1,110,426,000. Capital Research Global Investors boosted its stake in Cigna Group by 140.2% in the third quarter. Capital Research Global Investors now owns 3,179,301 shares of the health services provider’s stock valued at $916,434,000 after acquiring an additional 1,855,897 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Cigna Group by 7.4% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,695,620 shares of the health services provider’s stock worth $777,012,000 after acquiring an additional 186,880 shares during the period. 86.99% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Nicole S. Jones sold 2,307 shares of Cigna Group stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $288.91, for a total value of $666,515.37. Following the sale, the insider directly owned 32,647 shares in the company, valued at $9,432,044.77. This trade represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Everett Neville sold 1,719 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $288.91, for a total transaction of $496,636.29. Following the completion of the sale, the insider directly owned 5,670 shares in the company, valued at approximately $1,638,119.70. This represents a 23.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on CI shares. UBS Group reaffirmed a “buy” rating and set a $375.00 price objective on shares of Cigna Group in a research note on Monday, February 9th. Wall Street Zen raised Cigna Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. Jefferies Financial Group raised their target price on Cigna Group from $310.00 to $333.00 and gave the stock a “buy” rating in a report on Monday, February 9th. TD Cowen boosted their target price on Cigna Group from $333.00 to $338.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, Robert W. Baird decreased their price objective on shares of Cigna Group from $372.00 to $315.00 and set an “outperform” rating for the company in a report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $333.11.

Cigna Group Stock Performance

Shares of CI stock opened at $267.15 on Monday. The company has a market capitalization of $70.40 billion, a P/E ratio of 12.04, a price-to-earnings-growth ratio of 0.93 and a beta of 0.27. Cigna Group has a 52 week low of $239.51 and a 52 week high of $350.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.74 and a current ratio of 0.74. The company’s 50 day moving average price is $279.60 and its two-hundred day moving average price is $282.70.

Cigna Group (NYSE:CI) last issued its quarterly earnings data on Thursday, February 5th. The health services provider reported $8.08 EPS for the quarter, topping analysts’ consensus estimates of $7.88 by $0.20. The business had revenue of $72.50 billion for the quarter, compared to analyst estimates of $69.53 billion. Cigna Group had a net margin of 2.17% and a return on equity of 19.46%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the business posted $6.64 earnings per share. Cigna Group has set its FY 2026 guidance at 30.250- EPS. On average, analysts expect that Cigna Group will post 29.77 earnings per share for the current fiscal year.

Cigna Group Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Thursday, March 5th will be paid a $1.56 dividend. This represents a $6.24 annualized dividend and a yield of 2.3%. The ex-dividend date is Thursday, March 5th. This is a positive change from Cigna Group’s previous quarterly dividend of $1.51. Cigna Group’s dividend payout ratio (DPR) is presently 28.13%.

Key Cigna Group News

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Sanford C. Bernstein upgraded Cigna to “outperform” and raised its price target to $358, citing PBM reform as a clearing event and improved outlook for Evernorth — a catalyst for multiple analysts to raise estimates. Bernstein upgrades CVS and Cigna, citing PBM reform as key clearing event
• Positive Sentiment: Zacks notes CI trades below the industry P/E and highlights Evernorth growth, steady earnings beats and buybacks as supports for the investment case — a valuation/earnings combo that helps explain buying interest. Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?
• Neutral Sentiment: A valuation review highlights recent share-price weakness versus the specialty-pharmacy growth narrative — useful context for investors weighing whether current discounts already reflect execution risks. Evaluating Cigna Group (CI) Valuation After Recent Share Price Weakness And Specialty Pharmacy Growth Narrative
• Neutral Sentiment: A head-to-head comparison with CVS frames Cigna as the play for stronger earnings quality and capital discipline, while reminding long-term investors to consider income, stability and valuation differences when choosing exposure. CVS vs Cigna: Which Healthcare Giant Belongs in Your Retirement Portfolio?
• Neutral Sentiment: Zacks’ broader industry outlook continues to single out major HMOs (including Cigna) as key players in a sector balancing tech-enabled growth and policy/operational headwinds. Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana and Centene
• Negative Sentiment: Barclays and commentators warn that the timing of a CEO change could surprise investors and introduce strategic/operational uncertainty during a critical execution window. Management transition risk may weigh on sentiment until plans are clearer. The Cigna Group (CI) CEO Change Timing May Come As Surprise to Some Investors, According to Barclays
• Negative Sentiment: Industry pieces flag escalating medical costs, nursing shortages and margin pressure as sector-wide risks that could blunt near-term earnings leverage for HMOs, including Cigna. 4 HMO Stocks to Watch Despite Escalating Costs, Nursing Shortage

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.